Search results
Showing 466 to 480 of 667 results for kidney or kidneys or renal
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Evidence-based recommendations on intrauterine laser ablation of placental vessels for treating twin-to-twin transfusion syndrome. This involves using a laser to seal off some of the blood vessels in the placenta so both babies receive a more equal amount of blood.
View recommendations for IPG198Show all sections
Sections for IPG198
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Biographies for all current members of the diagnostics advisory committee.
Biographies for all current members of the diagnostics advisory committee.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.
View recommendations for IPG808Show all sections
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Percutaneous radiofrequency ablation of renal cancer (IPG91)
This guidance has been updated and replaced by NICE interventional procedure guidance 353.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.